BioMarin Pharmaceutical Inc. (BMRN)

85.90
2.01 2.29
NASDAQ : Health Technology
Prev Close 87.91
Open 87.71
Day Low/High 85.29 / 87.75
52 Wk Low/High 79.13 / 106.74
Volume 939.09K
Avg Volume 1.30M
Exchange NASDAQ
Shares Outstanding 179.07M
Market Cap 15.46B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

Two Small-Caps and One Mid-Cap Stock I Like So Far in 2019

It has been a better year for the Russell 2000 and the small-caps it represents.

BioMarin Highlights Key Milestones For 2019 At 37th Annual J.P. Morgan Healthcare Conference In San Francisco

BioMarin Highlights Key Milestones For 2019 At 37th Annual J.P. Morgan Healthcare Conference In San Francisco

Completed Enrollment of Subject Cohort to Support BLA Submission Through Accelerated Approval (AA) Pathway for Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A

BioMarin Pharmaceutical Becomes #1 Most Shorted Nasdaq 100 Component, Replacing Henry Schein

BioMarin Pharmaceutical Becomes #1 Most Shorted Nasdaq 100 Component, Replacing Henry Schein

The most recent short interest data has been released for the 11/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

BioMarin Pharmaceutical Becomes #2 Most Shorted Nasdaq 100 Component, Replacing Hasbro

BioMarin Pharmaceutical Becomes #2 Most Shorted Nasdaq 100 Component, Replacing Hasbro

The most recent short interest data has been released for the 10/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASPS, BMRN, CNHI, GTIM, JHX, NXEOU, PICO, USAP, VTSI, WUBA Downgrades: ABCB, CTRP, FDP, GBLI, MHLD, PDLI, SMCI, TV Initiations: BHF, PLXP Read on to get TheStreet Quant Ratings' detailed report:

3 Biotech Stock Favorites to Bet on Today: Top Analysts

3 Biotech Stock Favorites to Bet on Today: Top Analysts

Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

Charts: BioMarin Pharmaceutical Could Rise 30% From Here

Charts: BioMarin Pharmaceutical Could Rise 30% From Here

I have not seen a bullish breakout from a large base pattern in a while.

BioMarin Paces a Very Strong Biotech Group

BioMarin Paces a Very Strong Biotech Group

Here's how BMRN's chart looks after its blistering gains.

Chart of the Day: BioMarin Pharmaceutical

BMRN is pacing the very strong biotech group.

Probing the Long Side of BioMarin

Probing the Long Side of BioMarin

Latest surge boosts chances of breakout in shares of BioMarin.

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Markets Keep Eye on China Presidential Speech; Biotechs Bounce -- ICYMI

Here's what you need to know for Monday, April 9.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

5 Top Stocks With 100% Buy Ratings Right Now

5 Top Stocks With 100% Buy Ratings Right Now

These five 'Strong Buy' stocks boast a double whammy of only buy ratings and big upside potential. After the market's recent plunge, this list is quite handy.

Why I Stay Very Focused on My Individual Stocks

Why I Stay Very Focused on My Individual Stocks

I do not need to come up with any grand arguments for a bullish or bearish bias. It happens by default.

7 Winners and Losers From Biggest Biotech Conference of 2017

7 Winners and Losers From Biggest Biotech Conference of 2017

Here are how some of the conference presenters are performing on the market Wednesday

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio Becoming Household Name With This Promising Cancer Treatment

Bluebird Bio stock is flying higher by 20% Monday, following an update of its promising cancer treatments, Jim Cramer said.

Allergan, BioMarin Hold Promise for 2018

Allergan, BioMarin Hold Promise for 2018

The stocks of these two larger-cap biopharma names seem poised to stage comebacks next year.

BioMarin Pharmaceutical Stock Sees Short Interest Expand By 10.3%

BioMarin Pharmaceutical Stock Sees Short Interest Expand By 10.3%

The most recent short interest data has been released for the 11/15/2017 settlement date, which shows a 842,388 share increase in total short interest for BioMarin Pharmaceutical Inc. , to 9,033,035, an increase of 10.28% since 10/31/2017.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

GOP Tax Fix Could Zero Out Orphan Drug Tax Credit

The hotly debated tax reform championed by the Trump White House needs to be paid for by spending cuts. One proposed change could eliminate the tax credit for companies developing treatments through the Orphan Drug Act.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

BioMarin Pharmaceutical: Cramer's Top Takeaways

BioMarin Pharmaceutical: Cramer's Top Takeaways

JJ Bienaime, CEO of orphan drugmaker BioMarin Pharmaceutical, gives Jim Cramer an update on the company's drug portfolio.

Rally's Not Waiting on Tax Reform: Cramer's 'Mad Money' Recap (Wed 10/18/17)

Rally's Not Waiting on Tax Reform: Cramer's 'Mad Money' Recap (Wed 10/18/17)

Jim Cramer says Washington has, for years, had an inflated view of itself when it comes to passing legislation that helps the economy.

TheStreet Quant Rating: D+ (Sell)